ZOLEDRONIC (Page 6 of 6)


Zoledronic Acid Injection 4 mg/5 mL single-use vial of concentrate

Carton of 1 vial………………………………………………NDC 68083-116-01

Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature].


  • Patients should be instructed to tell their doctor if they have kidney problems before being given Zoledronic acid Injection.
  • Patients should be informed of the importance of getting their blood tests (serum creatinine) during the course of their Zoledronic acid Injection therapy.
  • Zoledronic acid Injection should not be given if the patient is pregnant or plans to become pregnant, or if she is breast-feeding.
  • Patients should be advised to have a dental examination prior to treatment with Zoledronic acid Injection and should avoid invasive dental procedures during treatment.
  • Patients should be informed of the importance of good dental hygiene and routine dental care.
  • Patients with multiple myeloma and bone metastasis of solid tumors should be advised to take an oral calcium supplement of 500 mg and a multiple vitamin containing 400 international units of Vitamin D daily.
  • Patients should be advised to report any thigh, hip or groin pain. It is unknown whether the risk of atypical femur fracture continues after stopping therapy.
  • Patients should be aware of the most common side effects including: anemia, nausea, vomiting, constipation, diarrhea, fatigue, fever, weakness, lower limb edema, anorexia, decreased weight, bone pain, myalgia, arthralgia, back pain, malignant neoplasm aggravated, headache, dizziness, insomnia, paresthesia, dyspnea, cough, and abdominal pain.
  • There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates, including Zoledronic acid. Before being given Zoledronic acid, patients should tell their doctor if they are aspirin-sensitive.

The brands listed are the registered trademarks of their respective owners and are not trademarks of Gland Pharma Limited.
Manufactured by:
Gland Pharma Limited
Hyderabad-500 043, INDIA
Revised: June 2014


Zoledronic acid Injection 4 mg/5 mL single-use vial
Vial NDC: 68083-116-01
Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature].
See package insert for Dosage and Administration and preparation of solution.
Do not mix with calcium-containing infusion solution.Discard unused portion.

image 3
(click image for full-size original)
ZOLEDRONIC zoledronic acid injection
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68083-116
Route of Administration INTRAVENOUS DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Inactive Ingredients
Ingredient Name Strength
MANNITOL 220 mg in 5 mL
SODIUM CITRATE 24 mg in 5 mL
# Item Code Package Description Multilevel Packaging
1 NDC:68083-116-01 1 VIAL in 1 CARTON contains a VIAL
1 5 mL in 1 VIAL This package is contained within the CARTON (68083-116-01)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA202930 09/20/2013
Labeler — Gland Pharma Limited (918601238)
Registrant — Gland Pharma Limited (918601238)
Name Address ID/FEI Operations
Gland Pharma Limited 918601238 ANALYSIS (68083-116), MANUFACTURE (68083-116)

Revised: 01/2015 Gland Pharma Limited

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.